<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6898960/results/search/disease/results.xml">
  <result pre=": Research Article Antiviral activity of mitoxantrone dihydrochloride against human" exact="herpes" post="simplex virus mediated by suppression of the viral immediate"/>
  <result pre="against human herpes simplex virus mediated by suppression of the" exact="viral" post="immediate early genes HuangQianghhwlqiang@163.com1HouJuemarquisjazz@163.com23YangPengyangpeng@suda.edu.cn4YanJunlociate@163.com3YuXiaoliangyxlzark@sina.com3ZhuoYingxhkzy_90@163.com5HeSudanhesudan@suda.edu.cn3http://orcid.org/0000-0002-1496-9141XuFengsz_xf@suda.edu.cn4[1], [2], [3], 0000 0001 0198"/>
  <result pre="molecule, mitoxantrone dihydrochloride, with potency against HSV-1-induced toxicity. Furthermore, the" exact="viral" post="titers and expression levels of HSV-1 viral proteins were"/>
  <result pre="toxicity. Furthermore, the viral titers and expression levels of HSV-1" exact="viral" post="proteins were potently reduced by the presence of MD"/>
  <result pre="analysis, we found that MD efficiently reduced the transcription of" exact="viral" post="genes that are essential for DNA synthesis, namely, UL5,"/>
  <result pre="which are required for the expression of early and late" exact="viral" post="gene products. Using immunofluorescence and western blot analysis, we"/>
  <result pre="Furthermore, we found that the reduction in the transcription of" exact="viral" post="immediate early genes was not related to the promoter"/>
  <result pre="stimulus. Although HSV-1 mainly causes innocuous diseases, such as labialis," exact="pharyngitis" post="and keratitis, it can also result in serious life-threatening"/>
  <result pre="keratitis, it can also result in serious life-threatening diseases, including" exact="encephalitis" post="[5–9]. Mature HSV-1 contains a large DNA genome core"/>
  <result pre="layer is referred to as tegument, which is composed of" exact="viral" post="proteins and mRNA. The outer layer is surrounded by"/>
  <result pre="gB, gC and gD, all of which are necessary for" exact="viral" post="entry [10, 11]. Once the HSV-1 virus enters the"/>
  <result pre="the cell nucleus and encodes several gene products that enable" exact="viral" post="replication [12, 13]. Viral gene expression is strictly regulated"/>
  <result pre="encodes several gene products that enable viral replication [12, 13]." exact="Viral" post="gene expression is strictly regulated in a cascade fashion."/>
  <result pre="or ICP27 significantly blocked the expression of early and late" exact="viral" post="genes [18]. Regulated by the immediate early genes, early"/>
  <result pre="approximately 2–8 h after infection. Most early genes are involved in" exact="viral" post="replication. As the infection progresses the late genes begin"/>
  <result pre="Most early genes are involved in viral replication. As the" exact="infection" post="progresses the late genes begin to be expressed, and"/>
  <result pre="whose expression also depends on immediate early genes. Some HSV-1" exact="viral" post="proteins are known to be necessary for viral DNA"/>
  <result pre="Some HSV-1 viral proteins are known to be necessary for" exact="viral" post="DNA synthesis and include proteins encoded by the UL5,"/>
  <result pre="so losing one of these proteins impedes the elongation of" exact="viral" post="DNA chains. There is a number of available antiviral"/>
  <result pre="of a nucleoside, acyclovir serves as a substrate for the" exact="viral" post="DNA polymerase and terminates the extension of the viral"/>
  <result pre="the viral DNA polymerase and terminates the extension of the" exact="viral" post="DNA to inhibit the proliferation of the HSV-1 virus"/>
  <result pre="inhibitor that shows promising efficacy in clinical trials targeting lymphomas," exact="breast cancer," post="and prostate cancer [25–27]. In the current study, using"/>
  <result pre="promising efficacy in clinical trials targeting lymphomas, breast cancer, and" exact="prostate cancer" post="[25–27]. In the current study, using a compound library"/>
  <result pre="efficacy in clinical trials targeting lymphomas, breast cancer, and prostate" exact="cancer" post="[25–27]. In the current study, using a compound library"/>
  <result pre="that MD effectively blocked not only HSV-1-induced toxicity but also" exact="viral" post="titers in multiple cell lines. MD also showed a"/>
  <result pre="[28] and identified MD as a potential inhibitor of human" exact="herpes" post="simples virus. MD has been reported as a topoisomerase"/>
  <result pre="has been used as an approved chemotherapy drug to treat" exact="lymphoma" post="and prostate cancer in consideration of its antitumour activity."/>
  <result pre="used as an approved chemotherapy drug to treat lymphoma and" exact="prostate cancer" post="in consideration of its antitumour activity. Since its effect"/>
  <result pre="as an approved chemotherapy drug to treat lymphoma and prostate" exact="cancer" post="in consideration of its antitumour activity. Since its effect"/>
  <result pre="MD by plaque forming assay. The results showed that the" exact="viral" post="titers were significantly suppressed by MD in HeLa cells"/>
  <result pre="these data show that MD robustly inhibits HSV-1-induced toxicity and" exact="viral" post="replication. Fig. 1 MD inhibited HSV-1 induced toxicity and"/>
  <result pre="viral replication. Fig. 1 MD inhibited HSV-1 induced toxicity and" exact="viral" post="proliferation in both human and mouse cells. a The"/>
  <result pre="1 h, then the cells were infected with HSV-1 for 6 h." exact="Viral" post="titers were determined by plaque forming assay. e L929"/>
  <result pre="(GFP) labeled HSV-1 for additional 16 h. Images were captured by" exact="inverted" post="fluorescence microscope MD reduces the expression levels of HSV-1"/>
  <result pre="DMSO or MD at indicated concentration for 1 h prior to" exact="infection" post="with HSV-1 for additional 6 h. Viral proteins were harvested"/>
  <result pre="for 1 h prior to infection with HSV-1 for additional 6 h." exact="Viral" post="proteins were harvested from cell lysates and the expression"/>
  <result pre="blot analysis MD shows antiviral efficacy even after HSV-1 entry" exact="Viral infection" post="is a complex procedure consisting of entry into host"/>
  <result pre="analysis MD shows antiviral efficacy even after HSV-1 entry Viral" exact="infection" post="is a complex procedure consisting of entry into host"/>
  <result pre="of entry into host cells, replication and transcription of the" exact="viral" post="genome, viral protein synthesis, viral assembly and release [10]."/>
  <result pre="into host cells, replication and transcription of the viral genome," exact="viral" post="protein synthesis, viral assembly and release [10]. Antiviral medications"/>
  <result pre="replication and transcription of the viral genome, viral protein synthesis," exact="viral" post="assembly and release [10]. Antiviral medications acting at any"/>
  <result pre="medications acting at any step of these processes will block" exact="viral infection." post="To investigate whether MD inhibited the expression levels of"/>
  <result pre="infection. To investigate whether MD inhibited the expression levels of" exact="viral" post="proteins even after HSV-1 entry, we washed cells with"/>
  <result pre="cells with PBS at the indicated time points after HSV-1" exact="infection" post="at which HSV-1 had completed entry (Fig. 3a). Then,"/>
  <result pre="worse the antiviral efficacy. MD consistently inhibited the expression of" exact="viral" post="proteins in both human and mouse cells even after"/>
  <result pre="cells even after HSV-1 entered cells (Fig. 3c and d)." exact="Viral" post="titers were also reduced in HSV-1-infected cells by post-treatment"/>
  <result pre="entry of virus into host cells. Fig. 3 MD inhibited" exact="viral" post="replication and the expression levels of HSV-1 proteins even"/>
  <result pre="the cells were washed twice with PBS and cultured in" exact="viral" post="free medium containing DMSO or MD (3.0 μM) for additional"/>
  <result pre="or MD (3.0 μM) for additional 6 h. The expression levels of" exact="viral" post="proteins were measured by western blot analysis. The viral"/>
  <result pre="of viral proteins were measured by western blot analysis. The" exact="viral" post="titers in HeLa cells (e) were measured by plaque"/>
  <result pre="measured by plaque forming assay MD suppresses the transcription of" exact="viral" post="genes Given that MD inhibited viral toxicity and suppressed"/>
  <result pre="suppresses the transcription of viral genes Given that MD inhibited" exact="viral" post="toxicity and suppressed the expression levels of viral proteins,"/>
  <result pre="MD inhibited viral toxicity and suppressed the expression levels of" exact="viral" post="proteins, we further confirmed whether the transcription levels of"/>
  <result pre="viral proteins, we further confirmed whether the transcription levels of" exact="viral" post="genes were also affected by MD. To examine the"/>
  <result pre="To examine the effects of MD on HSV-1 gene expression," exact="total" post="RNA was extracted from the treated cells, and Q-PCR"/>
  <result pre="as UL5, UL8, UL9, UL42 and UL52 are required for" exact="viral" post="DNA replication. We found that the transcription levels of"/>
  <result pre="which are required for the expression of early and late" exact="viral" post="gene products (Fig. 4c). These results suggest that MD"/>
  <result pre="immediate early genes. Fig. 4 MD suppressed the transcription of" exact="viral" post="genes. a-c L929 was pretreated with DMSO or MD"/>
  <result pre="with DMSO or MD (3.0 μM) for 1 h prior to HSV-1" exact="infection" post="for additional 2 h. The expression levels of indicated genes"/>
  <result pre="ICP0, which suggests that MD interfered with the transcription of" exact="viral" post="immediate early genes without affecting the promoter activity of"/>
  <result pre="[30–32]. We further tested whether MD suppressed the expression of" exact="viral" post="genes by disturbing the NF-κB pathway. Both viral evasion"/>
  <result pre="expression of viral genes by disturbing the NF-κB pathway. Both" exact="viral" post="evasion and antiviral cytokines such as TNF-α are able"/>
  <result pre="to be involved in the regulation of cytokine production and" exact="viral" post="replication [32–34], so we also investigated whether this pathway"/>
  <result pre="is a highly contagious virus that establishes a lifelong latent" exact="infection" post="in host cells. During the latent period, the virus"/>
  <result pre="period, the virus infects sensory neurons near the site of" exact="primary" post="infection, and the virions hide in the nucleus of"/>
  <result pre="RNA polymerase II in a highly regulated cascade. Once the" exact="viral" post="genome invades the host nucleus, the immediate early genes,"/>
  <result pre="including ICP0 and ICP4, play an essential role in initiating" exact="viral" post="transcription. Regulated by the immediate early genes, early genes"/>
  <result pre="after infection. The products of early genes are involved in" exact="viral" post="replication, while the products of late genes are usually"/>
  <result pre="a number of diseases ranging from simple cold sores to" exact="keratitis" post="and lethal encephalitis [5–9]. Current anti-HSV-1 drugs including acyclovir,"/>
  <result pre="diseases ranging from simple cold sores to keratitis and lethal" exact="encephalitis" post="[5–9]. Current anti-HSV-1 drugs including acyclovir, penciclovir and foscarnet"/>
  <result pre="[5–9]. Current anti-HSV-1 drugs including acyclovir, penciclovir and foscarnet are" exact="viral" post="DNA synthesis inhibitors. Acyclovir and penciclovir are commonly used"/>
  <result pre="DNA polymerase and prevents chain elongation and synthesis of the" exact="viral" post="DNA. Penciclovir exerts antiviral activity by a similar mechanism"/>
  <result pre="site on the herpesvirus DNA polymerase [24]. However, with the" exact="chronic" post="administration of anti-HSV drugs, drug-resistant HSV-1 strains have become"/>
  <result pre="been reported that MD has antitumour effects, especially against lymphoma," exact="breast cancer" post="and prostate cancer, by targeting DNA topoisomerase II [25–27]."/>
  <result pre="reported that MD has antitumour effects, especially against lymphoma, breast" exact="cancer" post="and prostate cancer, by targeting DNA topoisomerase II [25–27]."/>
  <result pre="MD has antitumour effects, especially against lymphoma, breast cancer and" exact="prostate cancer," post="by targeting DNA topoisomerase II [25–27]. However, its anti-HSV-1"/>
  <result pre="Further experiments demonstrated that MD suppressed GFP-tagged HSV-1 replication and" exact="viral" post="titers in host cells. We tested our hypothesis, that"/>
  <result pre="antiviral activity against HSV-1 by inhibiting the expression levels of" exact="viral" post="proteins. We found that the expression levels of viral"/>
  <result pre="of viral proteins. We found that the expression levels of" exact="viral" post="genes, including ICP6 and gB, were significantly suppressed by"/>
  <result pre="Therefore, we found that MD blocked HSV-1-induced toxicity and suppressed" exact="viral" post="protein synthesis. Given that MD can interact with topoisomerase"/>
  <result pre="synthesis, examination of whether MD reduces the expression level of" exact="viral" post="genes by directly binding topoisomerase II is a promising"/>
  <result pre="possible mechanism of antiviral efficacy of MD in the future." exact="Viral infection" post="is a complex process consisting of virus entry into"/>
  <result pre="mechanism of antiviral efficacy of MD in the future. Viral" exact="infection" post="is a complex process consisting of virus entry into"/>
  <result pre="virus entry into host cells, replication and transcription of the" exact="viral" post="genome, viral protein synthesis, viral assembly, and release [35]."/>
  <result pre="into host cells, replication and transcription of the viral genome," exact="viral" post="protein synthesis, viral assembly, and release [35]. Antiviral medications"/>
  <result pre="replication and transcription of the viral genome, viral protein synthesis," exact="viral" post="assembly, and release [35]. Antiviral medications act by impeding"/>
  <result pre="these steps. To elucidate whether MD protects cells from HSV-1" exact="infection" post="at viral entry or post viral entry, we changed"/>
  <result pre="To elucidate whether MD protects cells from HSV-1 infection at" exact="viral" post="entry or post viral entry, we changed the order"/>
  <result pre="protects cells from HSV-1 infection at viral entry or post" exact="viral" post="entry, we changed the order in which HSV-1 and"/>
  <result pre="added to cells. The results showed that MD still suppressed" exact="viral" post="protein synthesis and viral titers in host cells even"/>
  <result pre="results showed that MD still suppressed viral protein synthesis and" exact="viral" post="titers in host cells even after the virus had"/>
  <result pre="host cells. Therefore, MD showed antiviral efficacy mainly by suppressing" exact="viral" post="protein synthesis rather than blocking the entry of viruses"/>
  <result pre="is also involved in the regulation of cytokine production and" exact="viral" post="replication [32]. Therefore, we focused on whether MD inhibits"/>
  <result pre="the activation of the NF-κB and MAPK pathways. MD interrupted" exact="viral" post="protein synthesis, so we also examined whether the transcription"/>
  <result pre="protein synthesis, so we also examined whether the transcription of" exact="viral" post="genes was interrupted in the presence of MD. We"/>
  <result pre="UL30, UL42 and UL52, all of which are necessary for" exact="viral" post="DNA synthesis, was inhibited by MD. Moreover, the HSV-1"/>
  <result pre="also reduced in the presence of MD. Therefore, MD inhibits" exact="viral" post="protein synthesis by interrupting the transcription of viral immediate"/>
  <result pre="MD inhibits viral protein synthesis by interrupting the transcription of" exact="viral" post="immediate early genes. As one of the immediate early"/>
  <result pre="that ICP0 plays a pivotal role during lytic and latent" exact="infection" post="[36, 37]. However, according to our results, MD had"/>
  <result pre="of ICP0, which suggests that MD interrupts the transcription of" exact="viral" post="immediate early genes without affecting the promoter activity of"/>
  <result pre="for the development of a novel therapeutic drug against HSV-1" exact="infectious disease" post="that relies on its effective anti-HSV-1 activity. Methods Antibodies"/>
  <result pre="the development of a novel therapeutic drug against HSV-1 infectious" exact="disease" post="that relies on its effective anti-HSV-1 activity. Methods Antibodies"/>
  <result pre="was generated according to previously instruction [38]. Cells and viruses" exact="Mouse" post="fibroblast cells (L929) and African green monkey kidney cells"/>
  <result pre="instruction [38]. Cells and viruses Mouse fibroblast cells (L929) and" exact="African" post="green monkey kidney cells (Vero) in which the viruses"/>
  <result pre="viruses were propagated was from ATCC (American Type Culture Collection)." exact="Mouse" post="embryonic fibroblasts (MEFs) were isolated from day 14.5–15.5 embryos."/>
  <result pre="levels according to the manufacturer’s instruction. Plaque forming assay The" exact="infection" post="of cells was performed at an MOI of 2"/>
  <result pre="stained with crystal violet solution (2%) Then by using the" exact="Inverted" post="microscope, the viral plaque formation were counted. Western blot"/>
  <result pre="violet solution (2%) Then by using the Inverted microscope, the" exact="viral" post="plaque formation were counted. Western blot analysis Cell pellet"/>
  <result pre="glycerol, 1% Triton X-100, 1 mM Na3VO4, 25mMβ-glycerolphosphate, 0.1 mM PMSF, a" exact="complete" post="protease inhibitor set (Roche). The resuspended cell pellet was"/>
  <result pre="The proteins were detected by using appropriate antibody. Determination of" exact="viral" post="RNA levels Viral total RNA for real-time PCR was"/>
  <result pre="detected by using appropriate antibody. Determination of viral RNA levels" exact="Viral" post="total RNA for real-time PCR was extracted by using"/>
  <result pre="by using appropriate antibody. Determination of viral RNA levels Viral" exact="total" post="RNA for real-time PCR was extracted by using TRIzol"/>
  <result pre="for 8 h. Cells were analyzed for GFP by Leica DMILLED" exact="inverted" post="microscope. Transfection and luciferase reporter assay The 293 T were"/>
  <result pre="bovine serum albumin (BSA) in PBS for 30 min, then the" exact="primary" post="antibody and secondary antibody was added successively. Nuclear was"/>
  <result pre="(BSA) in PBS for 30 min, then the primary antibody and" exact="secondary" post="antibody was added successively. Nuclear was stained with DAPI."/>
  <result pre="Herpes simplex virus-1 MD Mitoxantrone dihydrochloride NF-κB Nuclear Factor-κB TNF-α" exact="Tumor" post="necrosis factor-α Publisher’s Note Springer Nature remains neutral with"/>
  <result pre="References References 1.BzikDJFoxBADeLucaNAPersonSNucleotide sequence specifying the glycoprotein gene, gB, of" exact="herpes" post="simplex virus type 1Virology1984133230131410.1016/0042-6822(84)90397-06324454 2.SmithJSRobinsonNJAge-specific prevalence of infection with"/>
  <result pre="gB, of herpes simplex virus type 1Virology1984133230131410.1016/0042-6822(84)90397-06324454 2.SmithJSRobinsonNJAge-specific prevalence of" exact="infection" post="with herpes simplex virus types 2 and 1: a"/>
  <result pre="herpes simplex virus type 1Virology1984133230131410.1016/0042-6822(84)90397-06324454 2.SmithJSRobinsonNJAge-specific prevalence of infection with" exact="herpes" post="simplex virus types 2 and 1: a global reviewJ"/>
  <result pre="areas of its target organs: local latency and reactivation in" exact="herpetic keratitis." post="Metab Pediatr Syst Ophthalmol. 1988;11(1):37-40. 4.KnottsFBCookMLStevensJGLatent herpes simplex virus"/>
  <result pre="reactivation in herpetic keratitis. Metab Pediatr Syst Ophthalmol. 1988;11(1):37-40. 4.KnottsFBCookMLStevensJGLatent" exact="herpes" post="simplex virus in the central nervous system of rabbits"/>
  <result pre="Pediatr Syst Ophthalmol. 1988;11(1):37-40. 4.KnottsFBCookMLStevensJGLatent herpes simplex virus in the" exact="central nervous system" post="of rabbits and miceJ Exp Med1973138374074410.1084/jem.138.3.7404353820 5.Delmonte S, Sidoti"/>
  <result pre="Stroppiana E, Stella ML, Costa C, Cavallo R, et al." exact="Recurrent" post="herpes labialis and HSV-1 herpes genitalis: which is the"/>
  <result pre="E, Stella ML, Costa C, Cavallo R, et al. Recurrent" exact="herpes" post="labialis and HSV-1 herpes genitalis: which is the link?"/>
  <result pre="C, Cavallo R, et al. Recurrent herpes labialis and HSV-1" exact="herpes" post="genitalis: which is the link? G Ital Dermatol Venereol."/>
  <result pre="which is the link? G Ital Dermatol Venereol. 2019;154(5):529-32. 6.DolinRGillFANahmiasAJGenital" exact="herpes" post="simplex virus type 1 infection--variability in modes of spreadJ"/>
  <result pre="link? G Ital Dermatol Venereol. 2019;154(5):529-32. 6.DolinRGillFANahmiasAJGenital herpes simplex virus" exact="type 1" post="infection--variability in modes of spreadJ Am Vener Dis Assoc1975221316173699"/>
  <result pre="in modes of spreadJ Am Vener Dis Assoc1975221316173699 7.HamroushAWelchJHerpes simplex" exact="epithelial" post="keratitis associated with daily disposable contact lens wearCont Lens"/>
  <result pre="modes of spreadJ Am Vener Dis Assoc1975221316173699 7.HamroushAWelchJHerpes simplex epithelial" exact="keratitis" post="associated with daily disposable contact lens wearCont Lens Anterior"/>
  <result pre="epithelial keratitis associated with daily disposable contact lens wearCont Lens" exact="Anterior" post="Eye201437322822910.1016/j.clae.2013.11.00724333040 8.RoweAMSt LegerAJJeonSDhaliwalDKKnickelbeinJEHendricksRLHerpes keratitisProg Retin Eye Res2013328810110.1016/j.preteyeres.2012.08.00222944008 9.RabinsteinAAHerpes virus"/>
  <result pre="Anterior Eye201437322822910.1016/j.clae.2013.11.00724333040 8.RoweAMSt LegerAJJeonSDhaliwalDKKnickelbeinJEHendricksRLHerpes keratitisProg Retin Eye Res2013328810110.1016/j.preteyeres.2012.08.00222944008 9.RabinsteinAAHerpes virus" exact="encephalitis" post="in adults: current knowledge and old mythsNeurol Clin201735469570510.1016/j.ncl.2017.06.00628962808 10.FarooqAVValyi-NagyTShuklaDMediators"/>
  <result pre="current knowledge and old mythsNeurol Clin201735469570510.1016/j.ncl.2017.06.00628962808 10.FarooqAVValyi-NagyTShuklaDMediators and mechanisms of" exact="herpes" post="simplex virus entry into ocular cellsCurr Eye Res201035644545010.3109/0271368100373484120465436 11.TurnerABruunBMinsonTBrowneHGlycoproteins"/>
  <result pre="Clin201735469570510.1016/j.ncl.2017.06.00628962808 10.FarooqAVValyi-NagyTShuklaDMediators and mechanisms of herpes simplex virus entry into" exact="ocular" post="cellsCurr Eye Res201035644545010.3109/0271368100373484120465436 11.TurnerABruunBMinsonTBrowneHGlycoproteins gB, gD, and gHgL of"/>
  <result pre="ocular cellsCurr Eye Res201035644545010.3109/0271368100373484120465436 11.TurnerABruunBMinsonTBrowneHGlycoproteins gB, gD, and gHgL of" exact="herpes" post="simplex virus type 1 are necessary and sufficient to"/>
  <result pre="Res201035644545010.3109/0271368100373484120465436 11.TurnerABruunBMinsonTBrowneHGlycoproteins gB, gD, and gHgL of herpes simplex virus" exact="type 1" post="are necessary and sufficient to mediate membrane fusion in"/>
  <result pre="in a Cos cell transfection systemJ Virol19987218738759420303 12.LacasseJJSchangLMDuring lytic infections," exact="herpes" post="simplex virus type 1 DNA is in complexes with"/>
  <result pre="cell transfection systemJ Virol19987218738759420303 12.LacasseJJSchangLMDuring lytic infections, herpes simplex virus" exact="type 1" post="DNA is in complexes with the properties of unstable"/>
  <result pre="complexes with the properties of unstable nucleosomesJ Virol20108441920193310.1128/JVI.01934-0920007274 13.PrestonCMRepression of" exact="viral" post="transcription during herpes simplex virus latencyJ Gen Virol200081Pt 111910.1099/0022-1317-81-1-110640537"/>
  <result pre="properties of unstable nucleosomesJ Virol20108441920193310.1128/JVI.01934-0920007274 13.PrestonCMRepression of viral transcription during" exact="herpes" post="simplex virus latencyJ Gen Virol200081Pt 111910.1099/0022-1317-81-1-110640537 14.HonessRWRoizmanBRegulation of herpesvirus"/>
  <result pre="herpesvirus macromolecular synthesis: sequential transition of polypeptide synthesis requires functional" exact="viral" post="polypeptidesProc Natl Acad Sci U S A19757241276128010.1073/pnas.72.4.1276165503 15.HonessRWRoizmanBRegulation of"/>
  <result pre="I. Cascade regulation of the synthesis of three groups of" exact="viral" post="proteinsJ Virol19741418194365321 16.WatsonRJClementsJBA herpes simplex virus type 1 function"/>
  <result pre="the synthesis of three groups of viral proteinsJ Virol19741418194365321 16.WatsonRJClementsJBA" exact="herpes" post="simplex virus type 1 function continuously required for early"/>
  <result pre="three groups of viral proteinsJ Virol19741418194365321 16.WatsonRJClementsJBA herpes simplex virus" exact="type 1" post="function continuously required for early and late virus RNA"/>
  <result pre="early and late virus RNA synthesisNature1980285576332933010.1038/285329a06246451 17.EverettRDICP0, a regulator of" exact="herpes" post="simplex virus during lytic and latent infectionBioessays200022876177010.1002/1521-1878(200008)22:8&amp;lt;761::AID-BIES10&amp;gt;3.0.CO;2-A10918307 18.UprichardSLKnipeDMHerpes simplex"/>
  <result pre="specific DNA replication genesJ Virol1996703196919808627723 19.CruteJJMocarskiESLehmanIRA DNA helicase induced by" exact="herpes" post="simplex virus type 1Nucleic Acids Res19881614A6585659610.1093/nar/16.14.65852840645 20.CruteJJTsurumiTZhuLAWellerSKOlivoPDChallbergMDMocarskiESLehmanIRHerpes simplex virus"/>
  <result pre="replicationCold Spring Harb Perspect Biol201249a01301110.1101/cshperspect.a01301122952399 22.WadeJCNewtonBFlournoyNMeyersJDOral acyclovir for prevention of" exact="herpes" post="simplex virus reactivation after marrow transplantationAnn Intern Med1984100682382810.7326/0003-4819-100-6-8236326632 23.SaralRBurnsWHLaskinOLSantosGWLietmanPSAcyclovir"/>
  <result pre="of antiviral action of penciclovir in MRC-5 cells infected with" exact="herpes" post="simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virusAntimicrob"/>
  <result pre="of penciclovir in MRC-5 cells infected with herpes simplex virus" exact="type 1" post="(HSV-1), HSV-2, and varicella-zoster virusAntimicrob Agents Chemother199236122747275710.1128/AAC.36.12.27471336346 25.WangSLLeeJJLiaoATComparison of"/>
  <result pre="26.Komeili-MovahhedTFouladdelSBarzegarEAtashpourSHossein GhahremaniMNasser OstadSMadjdZAziziEPI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7" exact="breast cancer" post="cell line to mitoxantrone chemotherapyIran J Basic Med Sci201518547247726124933"/>
  <result pre="GhahremaniMNasser OstadSMadjdZAziziEPI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast" exact="cancer" post="cell line to mitoxantrone chemotherapyIran J Basic Med Sci201518547247726124933"/>
  <result pre="drug resistance in cancerNanotechnology201627101570110.1088/0957-4484/27/1/01570126595807 28.HouJZhangZQiangHYanJZhangXYuXTanGZhengCFengXHeSAntiviral activity of PHA767491 against human" exact="herpes" post="simplex virus in vitro and in vivoBMC Infect Dis201717121710.1186/s12879-017-2305-028320320"/>
  <result pre="in vitro and in vivoBMC Infect Dis201717121710.1186/s12879-017-2305-028320320 29.SalvucciLABonneauRHTevethiaSSPolymorphism within the" exact="herpes" post="simplex virus (HSV) ribonucleotide reductase large subunit (ICP6) confers"/>
  <result pre="to induce NF-κB activationAnn N Y Acad Sci201010961899610.1196/annals.1397.074 31.HiscottJKwonHGéninPHostile takeovers:" exact="viral" post="appropriation of the NF-kappaB pathwayJ Clin Investig2001107214310.1172/JCI1191811160127 32.GoswamiDMahapatraADBanerjeeSKarAOjhaDMukherjeePKChattopadhyayDBoswellia serrata"/>
  <result pre="Clin Investig2001107214310.1172/JCI1191811160127 32.GoswamiDMahapatraADBanerjeeSKarAOjhaDMukherjeePKChattopadhyayDBoswellia serrata oleo-gum-resin and beta-boswellic acid inhibits HSV-1" exact="infection" post="in vitro through modulation of NF-small ka, CyrillicB and"/>
  <result pre="ka, CyrillicB and p38 MAP kinase signalingPhytomedicine2018519410310.1016/j.phymed.2018.10.01630466633 33.GillisPAOkagakiLHRiceSAHerpes simplex virus" exact="type 1" post="ICP27 induces p38 mitogen-activated protein kinase signaling and apoptosis"/>
  <result pre="kinase signaling and apoptosis in HeLa cellsJ Virol2009834176710.1128/JVI.01944-0819073744 34.ChenDSuAFuYWangXLvXXuWXuSWangHWuZHarmine blocks" exact="herpes" post="simplex virus infection through downregulating cellular NF-κB and MAPK"/>
  <result pre="and apoptosis in HeLa cellsJ Virol2009834176710.1128/JVI.01944-0819073744 34.ChenDSuAFuYWangXLvXXuWXuSWangHWuZHarmine blocks herpes simplex" exact="virus infection" post="through downregulating cellular NF-κB and MAPK pathways induced by"/>
  <result pre="apoptosis in HeLa cellsJ Virol2009834176710.1128/JVI.01944-0819073744 34.ChenDSuAFuYWangXLvXXuWXuSWangHWuZHarmine blocks herpes simplex virus" exact="infection" post="through downregulating cellular NF-κB and MAPK pathways induced by"/>
  <result pre="and MAPK pathways induced by oxidative stressAntivir Res20151232710.1016/j.antiviral.2015.09.00326348003 35.BedadalaGRPalemJRGrahamLHillJMMcferrinHEHsiaSCLytic HSV-1" exact="infection" post="induces the multifunctional transcription factor early growth Response-1 (EGR-1)"/>
  <result pre="36.ZhangJWangKWangSZhengCHerpes simplex virus 1 E3 ubiquitin ligase ICP0 protein inhibits" exact="tumor" post="necrosis factor alpha-induced NF-κB activation by interacting with p65/RelA"/>
  <result pre="with p65/RelA and p50/NF-κB1J Virol20138723129351294810.1128/JVI.01952-1324067962 37.LiuMSchmidtEEHalfordWPICP0 dismantles microtubule networks in" exact="herpes" post="simplex virus-infected cellsPLoS One201056e1097510.1371/journal.pone.001097520544015 38.HeSWangLMiaoLWangTDuFZhaoLWangXReceptor interacting protein kinase-3 determines"/>
 </snippets>
</snippetsTree>
